Background: Surgical resection of PAC followed by adjuvant therapy is the standard of care for localized resectable tumors. Surgical resection, with clear margins, of borderline resectable (BR) or locally advanced (LA) tumors remains quite challenging. NAT could potentially improve outcomes but there are no clear recommendations in this regards for upfront unresectable PAC. Herein, we report our experience with different NAT modalities used in BR and LA PAC. Methods: Medical records of patients identified in our medical database as BR or LA PAC and treated with NAT at Centre Hospitalier de l'Université de Montréal (CHUM) were retrospectively reviewed. Recist criteria were used for response assessment. Descriptive statistics and Kaplan-Meier were used for statistical purposes. Results: In total, ninety patients met the inclusion criteria (50 BR, 40 LA tumors). Chemotherapy, mostly FOLFIRINOX, was the only modality used in 51 patients (56.6%). Twenty-three patients (25.3%) received concurrent chemoradiation and sixteen patients (17.7%) received sequential chemotherapy and chemoradiation. Tumor resection was possible in 44 patients, 32 BR patients (R0: 68.7%) and 12 LA patients (R0: 75%).
Introduction
Pancreatic adenocarcinoma (PAC) is an aggressive disease that ranks as the fourth leading cause of cancer-related mortality in the United States, with a relatively short overall survival (OS) compared to other malignancies. The estimated 5-year survival rate is about 8.5% according to the most recent update by the Surveillance, Epidemiology, and End Results program for cases between 2008 and 2014 and 6.9% according to the Canadian Cancer Society 2017 statistics [1, 2] .
Surgery is the main modality with curative potential. However, resectable tumors account for less than 20% of all pancreatic cancers [3] . In the adjuvant setting, modified FOLFIRINOX (Folinic Acid (Leucovorin)-Fluorouracil-Irinotecan-Oxaliplatin) recently demonstrated promising improvements compared Gemcitabine monotherapy, thereby becoming the new standard for patients with a good performance status (PS) [4] . Older patients, or those with a more pronounced co-morbidity profile, might benefit from the less intense combination of Gemcitabine/Capecitabine, which was also shown to be superior to Gemcitabine monotherapy [5] . Alternatively, approximately half of the patients with PAC could present with upfront metastatic disease, known for its dismal prognosis and little improvements in survival over the past decade, despite the use of a few combination regimens [6, 7] . However, tumours presenting with vascular involvement are further classified into Borderline resectable (BR) or locally advanced (LA) according to the type and degree of vessel involvement (Table-1) [8] . BR tumors can be subject to upfront resection, but this is associated with a high likelihood of positive margins which could ultimately lead to local or distant recurrence. Furthermore, nonresectable LA tumours may be considered for resection only if they respond to NAT. Although there is limited evidence for the best preoperative strategy, neoadjuvant chemotherapy or chemoradiotherapy might represent an effective approach to increase the rate of surgical resection with negative margins (R0) thus improving survival rates [9] . Based on this, we aimed to retrospectively review our data and define the best available preoperative strategy. 
Respectability

Status
Methods
Study population
Analytical variables
The patients' clinical records were reviewed from the time of diagnosis until the first notation of death or the date of last contact. We retained information relating to baseline patient and tumor characteristics. Patients were categorized into different treatment arms depending on which chemotherapy regimen they received and whether it was Responding tumors with a plane of cleavage were taken to operation. Progressing disease, either local or with metastasis were sent for palliative treatments. Patients with tumor stability and still considered candidates for surgical resection received a second modality of treatment. Neoadjuvant therapy with a sequence of more than 1 treatment modality had a tendency for higher rates of resection and R0 resection but was statistically nonsignificant when compared to other groups (Table 3) .
Treatment considerations
Statistical considerations
Results
Survival analysis
Disease-free survival of resected patients was 12.3 months.
Median PFS and mOS were 15.2 months and 22.4 months, respectively, for the entire cohort, with no difference between BR and LA patients (Figure 1) . [21] . A prospective trial held in Korea, with a small cohort of patients, demonstrated improvements both in terms of overall survival and R0 resection rates through the use of neoadjuvant chemoradiotherapy compared to upfront surgery followed by adjuvant treatment [22] . Larger prospective randomized trials are needed to confirm these results.
As a retrospective analysis held in a single institution on a limited number of patients, our study is inherently limited by the potential for selection bias. Our analysis lacks a comparative group, especially in borderline resectable tumors to confirm the superiority of this approach on upfront surgical resection in terms of resection, survival, and recurrence rates. We intended to verify the prognostic value of Ca 19.9 on survival or as a selection factor that favors resection, but the number of patients with available pre and post-operative values was too limited to draw conclusions.
In summary, there is no clear consensus that recommends neoadjuvant therapy, and the optimal therapy for BR and LA pancreatic tumors remains to be determined and might differ amongst different centers of expertise. In partially responding tumors, continuing chemotherapy or switching to chemoradiotherapy needs to be more clarified with proper selection criteria. Yet, neoadjuvant therapy with chemotherapy and/or chemoradiotherapy appears to improve patients' resection outcomes and survival rates and should be considered in select patients whenever possible.
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